Angeles Therapeutics

Angeles Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of solid tumors. Spun out from the City of Hope, the company leverages foundational research in immunology and synthetic biology to overcome the challenges of the immunosuppressive tumor microenvironment. Its lead program targets prostate stem cell antigen (PSCA) for patients with metastatic castration-resistant prostate cancer. By optimizing CAR design and T-cell persistence, Angeles Therapeutics aims to provide curative options for cancers that have historically been resistant to immunotherapy.